期刊文献+

HBV-M阳性肺结核患者抗结核化疗的探讨 被引量:1

A STUDY ON THE ANTITUBERCULOSIS CHEMOTHERAPY FORPULMONARY TUBERCULOUS PATIENTS WITH POSITIVE HBV-M
下载PDF
导出
摘要 探讨HBV-M阳性肺结核患者抗结核化疗对肝功能的影响。方法:采用酶联免疫吸附试验(ELISA)法检测178例肺结核患者HBV-M、观察执结核化疗中肝功能变化与HBV-M的关系。结果:178例肺结核患者中HBV-M阳性92例(51.7%)、阴性86例(48.3%)、化疗期间肝功能异常分别为34.8%和9.4%(P<0.001)。单阳祖、双阳组和三阳组肝功能异常分别为23.1%,44.4%和57.7%,三阳组显著高于单阳组和双阳组(P<0.05)、结论HBV-M阳性肺结核患者可用含INH、RFP和P2A方案,但应并用保肝药。HBSAg(+)、HBeAg(+)、HBCAb(+)模式最好不用P2A。 Objective: To study the effects of antituberculosis chemotherapy on liver function in the pulmonary tuberculosis patients withpositive HBV-M. Methods: HBV-M and the liver function of 178 patients with pulmonary tuberculosis were investigated. Therelationship between the abnormal liver function and HBV-M during antituberculosis chemotherapy was observed. Results:Positive and negative fate of HBV-M among 178 patients was 51.7% and 48.3% respectively. 34.8% cases (32/92) with positiveHBV-M and 9.3% cases (8/86) with negative HBV-M showed abnormal liver function during antituberculosis chemotherapy,which showed a significant difference (P<0.01). The rate of abnormal liver function in one-positive group (HBsAg. HBeAg andHBcAb), two-positive group (HBsAg. HBeAg and HBsAg. HBcAb) and three-posihve group (HBsAg. HBeAg. HBcAb,andHBsAg. HBeAb. HBcAb) was 23.1%, 44.4% and 57.7% respectively. Comparing with the other two groups, there was a significantdifference in three-positive group (P<0.05). Conclusions: The chemotherapeutic programme of INF. RFP and PZA may bechosen for the pulmonary tuberculosis patients with positive HBV-M. PZA is not Suitable for the patients with positive HBsAg.HBeAg and HBcAb.
作者 朱同刚
出处 《中国现代医学杂志》 CAS CSCD 1999年第12期7-9,共3页 China Journal of Modern Medicine
关键词 肺结核 HBV-M 抗结核化疗 肝功能 治疗 Pulmonary Tuberculosis Hepatitis B Virus Mark (HBV-M) Antituberculosis Chemotherapy Liver Function
  • 相关文献

参考文献11

二级参考文献26

  • 1韩素霖,蔡斌.抗结核药物对乙肝病毒标志物阳性者肝功能的影响[J].中国防痨杂志,1994,16(2):63-64. 被引量:32
  • 2娄乐山,常曦莲.几种特殊情况抗结核药物的合理应用[J].中国实用内科杂志,1995,15(4):246-247. 被引量:13
  • 3[4]Chen J. P., Charles, & Jaggi,B. L. The Association between independent nonexecutive directors,family control and financial disclosures. Journal of Accounting and Public Ploicy, 1998.
  • 4[5]Chow, C., & Wong- Boren,A. Voluntary financial disclosure by Mexican corporations. The Accounting Review, 62(3) :pp533-541,1987.
  • 5[6]Esterbrook & Fischel. Mandatory Disclosure and the Protection of Investor. 70 Va. L. Rev. Pp669,1984.
  • 6[7]FASB. Improving Business Reporting: Insights into Enhancing Voluntary Disclosures, 2001.
  • 7[8]Forker, J. J. Corporate governance and disclosure quali ty. Accounting and Business Research, 22 (86): pp1 11 -124,1992.
  • 8[9]Givoly, D., Palmon, D. Timeliness of annual earnings announcement:Some empirical evidence. Accounting Review 57: pp486 - 508,1982.
  • 9[10]Grossman, S.J. The informational role of warranties and private disclosure about product quality. Journal of
  • 10[11]Jenson & Meckling. Theory of the Firm:Managerial Behavior, Agency Costs and Ownership Structure. J. Fin.Econ: pp305,1976.

共引文献250

同被引文献7

  • 1邢同京,陈加保,张光曙,甘天福,丁明权,阎承玉.利福平与异烟肼合用致肝损害的临床与病理分析[J].中华结核和呼吸杂志,1997,20(1):33-35. 被引量:80
  • 2王浩 王钦茂.抗结核药所致肝损害防治进展[J].临床肝胆病杂志,1990,6(3):125-125.
  • 3龙大钰.吴健.医学科学国际组织委员会(CLOMS)关于药物所致肝脏疾患的标准.见:叶维法.钟振义.肝炎学大典,第1版.天津:天律科学技术出版社.1996:1275—1277.
  • 4Joint Tuberculosis Committee of the British Thoracic Society.Chemotherupy and management of tuberculcsis in the United Kingdom:recommendations Thorax.1998;53:536-548.
  • 5Dessing M, Wilcke JIT, Askgaard DS. Liver injury dining antituberculosis treatment: an ll year study. Tubere Lung Dis, 1996; 77: 335-340.
  • 6张培元.应重视肝脏疾患时抗结核药物肝损害[J].中华结核和呼吸杂志,1998,21(11):643-644. 被引量:202
  • 7朱同刚,罗永艾.结核病的短程标准化学疗法[J].国外医学(内科学分册),2000,27(2):65-69. 被引量:2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部